^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Juvenile Myelomonocytic Leukemia
    Drug:azacitidine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/20/2022
    Excerpt:
    VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of...Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).